NCT02058277View on ClinicalTrials.gov

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

Healthy

Interventions

DRUG

bosutinib or bosutinib + aprepitant

Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)

Trial Locations (1)

32720

Pfizer Investigational Site, DeLand

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT02058277 - A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers | Biotech Hunter | Biotech Hunter